Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.

Leukemia - 1 May 2022

Fournier Elise, Heiblig Maël, Lespinasse Christine, Flandrin-Gresta Pascale, Geay Antoine, Miguet Laurent, Fenwarth Laurene, Vallat Laurent, Soubeyrand Brigitte, Marceau-Renaut Alice, Plesa Adriana, Preudhomme Claude, Sujobert Pierre, Hayette Sandrine, Duployez Nicolas, Huet Sarah

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation
Share to Neoplasm, Residual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nuclear Proteins

Source

Identifiers

PMID: 35256762
DOI: 10.1038/s41375-022-01534-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.PMID 35256762Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemiaSemantic proximity Read ↗

Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Biological and clinical consequences of NPM1 mutations in AML.Semantic proximity Read ↗

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemiaSemantic proximity Read ↗

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.Semantic proximity Read ↗

Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.Semantic proximity Read ↗

Clonal evolution of NPM1 gene mutation in relapsed normal karyotype acute myeloid leukemia.Semantic proximity Read ↗

Targeted therapy in NPM1-mutated AML: Knowns and unknownsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.